G. Springett

发表

Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies

D. Shibata, E. Siegel, W. Fulp, 2015, Investigational New Drugs.

Non‐kinase second‐messenger signaling: new pathways with new promise

D. Spriggs, H. Kawasaki, G. Springett, 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

E. Jaffee, T. Greten, T. Crocenzi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone

J. Maurel, H. Wasan, J. Spano, 2009, British Journal of Cancer.

Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent

W. Anderson, R. Blaese, R. Moen, 1989, Journal of virology.

Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma

R. Gonzalez, M. Bui, Dung-Tsa Chen, 2015, Sarcoma.

Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.

A. Gangi, R. Shridhar, M. Malafa, 2018, Journal of vascular and interventional radiology : JVIR.

Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer

R. Shridhar, W. Fulp, M. Malafa, 2016, Annals of Surgical Oncology.

Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy

T. Strom, R. Shridhar, M. Malafa, 2017, Acta oncologica.

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker

P. Munster, D. Sullivan, A. Daud, 2009, British Journal of Cancer.

Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma

A. Sarnaik, K. Kodumudi, N. Vohra, 2013, Cancer Immunology, Immunotherapy.

A Genome-Wide Investigation of MicroRNA Expression Identifies Biologically-Meaningful MicroRNAs That Distinguish between High-Risk and Low-Risk Intraductal Papillary Mucinous Neoplasms of the Pancreas

T. Yeatman, D. Coppola, S. Yoder, 2015, PloS one.

Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer.

R. Shridhar, M. Malafa, S. Hoffe, 2016, Journal of gastrointestinal oncology.

Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer.

E. Jaffee, T. Greten, T. Crocenzi, 2013 .

Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer.

T. Strom, R. Shridhar, M. Malafa, 2016, Journal of gastrointestinal oncology.

Patterns of recurrence and long-term outcomes in patients who underwent pancreatectomy for intraductal papillary mucinous neoplasms with high grade dysplasia: implications for surveillance and future management guidelines.

M. Malafa, M. Doepker, B. Centeno, 2017, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Cyst fluid carcinoembryonic antigen level is not predictive of invasive cancer in patients with intraductal papillary mucinous neoplasm of the pancreas.

M. Malafa, Y. Chen, B. Centeno, 2012, JOP : Journal of the pancreas.

Neoadjuvant GTX Chemotherapy and IMRT‐based chemoradiation for borderline resectable pancreatic cancer

Jongphil Kim, M. Malafa, S. Hoffe, 2011, Journal of surgical oncology.

Adjuvant radiation provides survival benefit for resected pancreatic adenocarcinomas of the tail.

T. Strom, R. Shridhar, M. Malafa, 2018, Journal of gastrointestinal oncology.

Multi-institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.

H. Soares, Jongphil Kim, H. Sanoff, 2016 .

Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis

S. Hoffe, A. Mahipal, G. Springett, 2016, American journal of clinical oncology.

Chemotherapy and IMRT-Based Chemoradiation for Borderline Resectable Pancreatic Cancer

Jongphil Kim, M. Malafa, S. Hoffe, 2012 .

Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies.

J. Doroshow, C. Takimoto, J. Dupont, 2004, Journal of Clinical Oncology.

Microsatellite instability in pancreatic cancer.

D. Coppola, A. Mahipal, G. Springett, 2016 .

Lysophosphatidic Acid Acyltransferase Beta Regulates mTOR Signaling

S. Sebti, H. Lawrence, M. Blaskovich, 2013, PLoS ONE.

Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies.

A. Hummer, J. Singer, J. Dupont, 2005, Cancer research.

Systematic Review and Case Series Report of Acinar Cell Carcinoma of the Pancreas.

D. Coppola, M. Malafa, S. Hoffe, 2016, Cancer control : journal of the Moffitt Cancer Center.

A family of cAMP-binding proteins that directly activate Rap1.

A M Graybiel, A. Graybiel, D. Housman, 1998, Science.

Pancreatic cancer presenting as a Sister Mary Joseph's nodule: case report and update of the literature.

B. Centeno, G. Springett, Vimala Yendluri, 2007, Pancreas.

Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.

A. Venook, P. Munster, A. Daud, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genesis of Pancreatic Ductal Neoplasia

B. Centeno, G. Springett, 2010 .

Abstract 1299: A phase I dose-escalation study of the safety, PK, and PD of vitamin E Δ-tocotrienol administered to subjects with resectable pancreatic exocrine neoplasia

S. Sebti, M. Malafa, R. Lush, 2011 .

Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma

T. Strom, R. Shridhar, M. Malafa, 2015, Acta oncologica.

Interim results of a randomized phase II study of PEGPH20 added to nab-paclitaxel/gemcitabine in patients with stage IV previously untreated pancreatic cancer.

A. Hezel, A. Bullock, X. Wu, 2016 .

A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia.

A. Graybiel, J. Canales, D. Housman, 1998, Proceedings of the National Academy of Sciences of the United States of America.

A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.

P. LoRusso, M. Gordon, S. Wind, 2015, Future oncology.

Lessons learned from a complete remission of advanced metastatic pancreatic ductal adenocarcinoma.

S. Hoffe, B. Centeno, G. Springett, 2012, Clinical advances in hematology & oncology : H&O.

Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

M. Borad, A. Daud, W. Messersmith, 2011, Clinical Cancer Research.

Pulmonary metastasectomy for suspected pancreaticobiliary cancer.

J. Fontaine, J. Pimiento, E. Toloza, 2016, The Journal of thoracic and cardiovascular surgery.

A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer

W. Fulp, S. Hoffe, A. Mahipal, 2015, Journal of Gastrointestinal Cancer.

Novel pancreatic cancer vaccines could unleash the army within.

G. Springett, 2014, Cancer control : journal of the Moffitt Cancer Center.

Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer.

T. Strom, S. Eschrich, D. Coppola, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.

E. Van Cutsem, D. Richel, J. Furuse, 2011, The Lancet. Oncology.

Leukocyte adhesion deficiency‐I variant syndrome (LAD‐Iv, LAD‐III): Molecular characterization of the defect in an index family

A. Weyrich, G. Zimmerman, G. Springett, 2012, American journal of hematology.

Outcomes of resected pancreatic cancer in patients age ≥70.

T. Strom, R. Shridhar, M. Malafa, 2015, Journal of gastrointestinal oncology.

Activity of fractionated radioimmunotherapy (RAIT) with 90Y clivatuzumab tetraxetan (90Y-hPAM4) plus gemcitabine (Gem) in advanced pancreatic cancer (APC): Final results from a two-part study.

T. Bekaii-Saab, D. Goldenberg, E. Mitchell, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of the WT 1 Tumor Suppressor in Murine Hematopoiesis

D. Housman, H. Rayburn, J. Kreidberg, 2002 .

Borderline resectable pancreatic cancer: on the edge of survival.

S. Hoffe, G. Springett, 2008, Cancer control : journal of the Moffitt Cancer Center.

Genetic structure of the dopamine receptor D4 gene (DRD4) and lack of association with schizophrenia in Japanese patients.

S. Kanba, N. Kinukawa, V. Stanton, 2007, Journal of psychiatric research.

Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies

J. Homsi, P. Munster, D. Sullivan, 2007, Clinical Cancer Research.

Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells

W. Guida, S. Sebti, Aslamuzzaman Kazi, 2009, Cell cycle.

A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia

S. Sebti, M. Malafa, Dung-Tsa Chen, 2015, EBioMedicine.

Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer

D. Shibata, E. Siegel, W. Fulp, 2015, Cancer Chemotherapy and Pharmacology.

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

Suzanne F. Jones, F. Gao, R. Govindan, 2007, Clinical Cancer Research.

Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage

T. Strom, R. Shridhar, M. Malafa, 2015, Surgical Endoscopy.

PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer

Brian G Morse, Jongphil Kim, B. Yue, 2015, Clinical nuclear medicine.

Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.

Ravi Shridhar, R. Shridhar, M. Malafa, 2013, International journal of radiation oncology, biology, physics.

Resected pancreatic cancer outcomes in the elderly.

T. Strom, R. Shridhar, M. Malafa, 2015, Journal of geriatric oncology.

Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy

R. Shridhar, W. Fulp, M. Malafa, 2014, Cancer.

Erratum: A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia (Proceedings of the National Academy of Sciences of the USA (1998) 95:22 (13278-13283))

A. Graybiel, J. Canales, D. Housman, 1999 .

Effects of a brief multimedia psychoeducational intervention on the attitudes and interest of patients with cancer regarding clinical trial participation: a multicenter randomized controlled trial.

C. Meade, P. Jacobsen, W. Fulp, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy.

R. Shridhar, W. Fulp, M. Malafa, 2017, Journal of gastrointestinal oncology.

Longitudinal cohort study to determine effectiveness of a novel simulated case and feedback system to improve clinical pathway adherence in breast, lung and GI cancers

R. Shimkhada, J. Peabody, A. Chiappori, 2016, BMJ Open.

Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials

D. Sullivan, J. Strosberg, A. Mahipal, 2015, American journal of clinical oncology.

A phase I dose-escalation study of SCH 900776, a selective inhibitor of checkpoint kinase 1 (CHK1), in combination with gemcitabine (Gem) in subjects with advanced solid tumors.

David S. Mendelson, Pamela N. Munster, Lee S. Rosen, 2010 .

Expression of programmed death ligand 1 (PD-L1) in malignant and nonmalignant pancreatic tissue.

D. Coppola, M. Malafa, Noman Ashraf, 2013 .

Induction gemcitabine-based chemotherapy and neoadjuvant stereotactic body radiation therapy achieve high margin-negative resection rates for borderline resectable pancreatic cancer

R. Shridhar, M. Malafa, S. Hoffe, 2012, Journal of Radiation Oncology.

Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer.

R. Shridhar, M. Malafa, S. Hoffe, 2011, Gastrointestinal cancer research : GCR.

A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results.

E. Jaffee, T. Greten, T. Crocenzi, 2014 .

Association analysis of adenosine A1 receptor gene (ADORA1) polymorphisms with schizophrenia in a Japanese population

N. Oribe, S. Kanba, A. Takata, 2009, Psychiatric genetics.

Radiosensensitivity Index Shows Promise for Predicting Outcomes With Adjuvant Radiation in Resected Pancreatic Cancer Patients

T. Strom, S. Eschrich, D. Coppola, 2014 .

Re-planning for compensator-based IMRT with original compensators.

Geoffrey G. Zhang, C. Stevens, V. Feygelman, 2011, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

Worse Overall Survival With Preoperative Biliary Drainage in Resectable Pancreatic Cancer Patients

T. Strom, R. Shridhar, M. Malafa, 2014 .